New combo therapy aims to delay prostate cancer relapse in patients with limited spread

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically proven adenocarcinoma of the prostate 2. Patients aged 18 years or more 3. PS 0-1 4. Previous radical treatment to the prostate (radiotherapy or surgery) 5. PSA increase of at least 3 assays in the same laboratory over the last 12 months. 6. 1-5 pelvic lymph node metastases detected with 18FCH-PET. A relapse in the dressing prostatectomy is associated possible. 7. Upper limit of lymph node metastases: aortic bifurcation 8. Respect dosimetric constraints to organs at risk 9. Treatment with hormone therapy may be started before inclusion, to a maximum of three months prior to Day 1 of radiotherapy. This hormone will necessarily be preceded by a free interval treatment of at least 6 months since the last injection, by adding the duration of action of this predictable injection (1, 3 or 6 months) 10. Patient affiliated to a social security scheme 11. Patient Information and written informed consent form signed Exclusion Criteria: 1. bone or visceral metastatic relapse associated 2. para-aortic nodal relapse (the upper limit is tolerated aortic bifurcation) 3. more than 5 lymph node metastases 4. Proof of metastases at initial diagnosis 5. Evidence of distant metastases in the pelvic lymph nodes or outside the prostate bed 6. prior pelvic lymph nodes Irradiation. Irradiation of the bed of the prostate is not an exclusion criterion, but the junction between prior irradiation bed prostatectomy and radiation field pelvic lymph nodes should be examined carefully 7. castration resistance defined by clinical or biochemical progression despite a combined androgen blockade 8. known contraindications to pelvic irradiation (eg, chronic inflammatory bowel disease, ...) 9. known contraindications to hormone therapy, according to standard recommendations in force 10. serious Hypertension not controlled by appropriate treatment 11. Other concomitant cancer or history of cancer (within 5 years prior to study entry), except basal cell or squamous cell carcinomas of the skin. 12. Patient with a psychological, familial, sociological or geographical potentially hampering compliance with the study protocol and follow-up schedule 13. Patient already included in another interventional study involving the approval of a CPP during his screening for the study OLIGOPELVIS 14. Private person of liberty or major trust